(Q54385774)

English

Lymphokine-activated killer (LAK) cells from human intestinal mucosa: Cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cells

scientific article published on April 1, 1988

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

Lymphokine-activated killer (LAK) cells from human intestinal mucosa: Cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cells (English)

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Victor Warren Fazio

4

object named as

Fazio VW

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

author name string

J. L. Trudel

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

K. R. Youngman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

G. A. West

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

C. Fiocchi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3361887

1 January 2023

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=3361887

1 January 2023

publication date

1 April 1988

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

full work available at URL

https://api.elsevier.com/content/article/PII:0022480488901886?httpAccept=text/xml

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

https://api.elsevier.com/content/article/PII:0022480488901886?httpAccept=text/plain

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Journal of Surgical Research

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

44

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

445-454

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

Prolongation of the disease-free interval in surgically treated rectal carcinoma

1

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Adjuvant Therapy of Colon Cancer — Results of a Prospectively Randomized Trial

2

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil

3

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma

4

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report

5

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated killer cells: a new approach to immunotherapy of cancer

6

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

7

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

10

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors

11

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lysis of human solid tumor cells by lymphokine-activated natural killer cells

12

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lysis of primary hepatic tumours by lymphokine activated killer cells

13

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

14

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2

15

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

16

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

17

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Lymphokine-activated and natural killer cell activity in human intestinal mucosa

20

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Isolation and functional characterization of human intestinal mucosal lymphoid cells

22

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Partial purification of human colonic carcinoma cells by sedimentation

23

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses

24

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Characterization of a renal cell carcinoma cell line suitable as a target for immunological studies in vitro and in the nu/nu mouse

26

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral bloo

29

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes

35

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

36

1 reference

10.1016/0022-4804(88)90188-6

https://api.crossref.org/works/10.1016/0022-4804(88)90188-6

1 January 2023

Identifiers

10.1016/0022-4804(88)90188-6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/3361887

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54385774&oldid=1799779624"